The new cancer diagnostic test is intended to identify patients more likely to benefit from a specific treatment. The collaboration will draw on Dako’s extensive experience within the development of cancer diagnostic tests and Osi Pharmaceuticals’s thorough knowledge in developing and commercializing novel pharmaceutical products.
Lars Holmkvist, CEO and president of Dako Denmark, said: “The future within oncology pharmacotherapy is in targeted therapies. Linking a drug with a diagnostic test is what you can call a triple win situation. Most importantly, the patient will receive relevant therapy from the start instead of a trial-and-error medication.
“Secondly, the pharmaceutical company may develop even more innovative and improved cancer therapies, thereby increasing the general health within society. Thirdly, Dako itself will continue to provide gold standard companion diagnostics to the market, thereby contributing to improve the overall healthcare costs.”